Becton Dickinson settles charges over infusion pump risks, SEC saysWASHINGTON, Dec 16 (Reuters) - The U.S. Securities and Exchange Commission said on Monday that it had settled charges with Becton Dickinson and Co. over allegations it misled investors about risks associated with its Alaris infusion pump.
The SEC said Becton Dickinson agreed to pay a $175 million civil penalty to settle the charges, which also allege that the company overstated its income by failing to disclose the costs of software repairs associated with the pump.
(Reporting by Caitlin Webber)
((caitlin.webber@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments